LONDON - Belluscura has entered into a joint venture with Separation Design Group and an undisclosed major medical device company to develop oxygen-based wound care solutions.
Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, has successfully completed its Phase 1 clinical trial of ...